Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-09-01
DOI
10.1038/s41467-021-25382-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
- (2021) Philip J.M. Brouwer et al. CELL
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
- (2021) Denis Y Logunov et al. LANCET
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2021) Zhiwei Wu et al. LANCET INFECTIOUS DISEASES
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
- (2021) Raches Ella et al. LANCET INFECTIOUS DISEASES
- SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
- (2021) Constantinos Kurt Wibmer et al. NATURE MEDICINE
- DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice
- (2021) Inga Szurgot et al. Scientific Reports
- Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2
- (2021) Gajanan N Sapkal et al. JOURNAL OF TRAVEL MEDICINE
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
- (2021) Katherine R W Emary et al. LANCET
- Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
- (2021) Delphine Planas et al. NATURE MEDICINE
- Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine
- (2021) Matan Levine-Tiefenbrun et al. NATURE MEDICINE
- Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
- (2021) Joseph E. Ebinger et al. NATURE MEDICINE
- Cell entry mechanisms of SARS-CoV-2
- (2020) Jian Shang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- SARS-CoV-2 infection protects against rechallenge in rhesus macaques
- (2020) Abishek Chandrashekar et al. SCIENCE
- Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
- (2020) Noe B. Mercado et al. NATURE
- Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
- (2020) Pauline Maisonnasse et al. NATURE
- Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
- (2020) Kizzmekia S. Corbett et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
- (2020) Evan J. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
- (2020) Jeffrey Seow et al. Nature Microbiology
- Reinfection with SARS-CoV-2: Implications for Vaccines
- (2020) Jeffrey I Cohen et al. CLINICAL INFECTIOUS DISEASES
- Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
- (2020) Xiancai Ma et al. IMMUNITY
- Correlates of protection against SARS-CoV-2 in rhesus macaques
- (2020) Katherine McMahan et al. NATURE
- Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
- (2020) Alicia T. Widge et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice
- (2020) Véronique Godot et al. PLoS Pathogens
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020
- (2020) Sara E. Oliver et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- DC Subsets Regulate Humoral Immune Responses by Supporting the Differentiation of Distinct Tfh Cells
- (2019) Aurélie Bouteau et al. Frontiers in Immunology
- TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs
- (2018) Liang Cheng et al. JOURNAL OF CLINICAL INVESTIGATION
- Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses
- (2017) Gerard Zurawski et al. JOURNAL OF VIROLOGY
- Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8+ and CD4+ T Cells
- (2016) Wenjie Yin et al. EBioMedicine
- Self-replicating alphavirus RNA vaccines
- (2014) Karl Ljungberg et al. Expert Review of Vaccines
- Raising Expectations For Subunit Vaccine
- (2014) John T. Schiller et al. JOURNAL OF INFECTIOUS DISEASES
- Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells
- (2013) Anne-Laure Flamar et al. AIDS
- Noncovalent Assembly of Anti-Dendritic Cell Antibodies and Antigens for Evoking Immune Responses In Vitro and In Vivo
- (2012) A.-L. Flamar et al. JOURNAL OF IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started